

Laura M Spring

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1870831/publications.pdf>

Version: 2024-02-01

86
papers

2,860
citations

304743

22
h-index

189892

50
g-index

87
all docs

87
docs citations

87
times ranked

3945
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor- ⁺ positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2022, 28, 821-830.	7.0	26
2	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	1.6	75
3	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. <i>Cancer Cell</i> , 2022, 40, 103-108.e2.	16.8	30
4	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. <i>Cancer Research</i> , 2022, 82, PD2-03-PD2-03.	0.9	0
5	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. <i>Cancer Research</i> , 2022, 82, P1-18-22-P1-18-22.	0.9	0
6	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). <i>Cancer Research</i> , 2022, 82, P1-14-02-P1-14-02.	0.9	1
7	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. <i>Cancer Research</i> , 2022, 82, P4-12-08-P4-12-08.	0.9	0
8	Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. <i>Cancer Research</i> , 2022, 82, OT1-12-05-OT1-12-05.	0.9	0
9	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. <i>Cancer Research</i> , 2022, 82, P3-23-02-P3-23-02.	0.9	0
10	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). <i>Cancer Research</i> , 2022, 82, PD5-11-PD5-11.	0.9	0
11	Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022, 82, P2-14-17-P2-14-17.	0.9	4
12	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	5
13	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	5.2	18
14	The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 723-734.	4.9	19
15	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 512-512.	1.6	22
16	Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1017-1017.	1.6	5
17	Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <i>ESR1</i> mutations and fusions. <i>Cancer Research</i> , 2022, 82, 5248-5248.	0.9	0
18	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS623-TPS623.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer.. Journal of Clinical Oncology, 2022, 40, e12521-e12521.	1.6	0
20	Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.. Journal of Clinical Oncology, 2022, 40, 1039-1039.	1.6	0
21	Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation. Cancer Research, 2022, 82, 2638-2638.	0.9	14
22	Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.. Journal of Clinical Oncology, 2022, 40, TPS624-TPS624.	1.6	2
23	Baseline preferences for digital information engagement in patients with breast cancer by age and status of diagnosis.. Journal of Clinical Oncology, 2022, 40, e24119-e24119.	1.6	0
24	Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. Clinical Breast Cancer, 2021, 21, e88-e95.	2.4	4
25	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413.	7.0	10
26	Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤ 45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0
27	Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer. , 2021, , .		0
28	Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR). Cancer Research, 2021, 81, OT-03-06-OT-03-06.	0.9	5
29	Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Research and Treatment, 2021, 188, 561-569.	2.5	7
30	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery, 2021, 11, 2474-2487.	9.4	92
31	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS603-TPS603.	1.6	4
32	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. Journal of Clinical Oncology, 2021, 39, 1570-1570.	1.6	1
33	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist, 2021, 26, 827-834.	3.7	28
34	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	1.6	40
35	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Gene Fusion. Oncologist, 2021, 26, 818-824.	3.7	8
36	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103.	5.2	17

#	ARTICLE	IF	CITATIONS
37	ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 85.	5.0	124
38	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
39	Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. <i>Npj Precision Oncology</i> , 2021, 5, 85.	5.4	1
40	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	36
41	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	2.0	3
42	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	3.0	16
43	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 515-524.	2.5	11
44	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	7.1	84
45	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097175.	0.9	2
46	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.8	24
47	Thermal Injury in a Patient Using a Scalp Cooling System to Prevent Chemotherapy-Induced Alopecia. <i>JCO Oncology Practice</i> , 2020, 16, 522-524.	2.9	0
48	Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. <i>Breast Journal</i> , 2020, 26, 1189-1198.	1.0	9
49	Identification of Somatic Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	7.0	12
50	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	13.7	260
51	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	27.0	12
52	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	7.0	403
53	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1066-1066.	1.6	13
54	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1094-1094.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology, 2020, 38, 505-505.	1.6	34
56	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. Journal of Clinical Oncology, 2020, 38, 531-531.	1.6	3
57	Factors associated with frequent insomnia among breast cancer survivors.. Journal of Clinical Oncology, 2020, 38, e24098-e24098.	1.6	0
58	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	5.4	25
59	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer, 2019, 19, 399-404.	2.4	27
60	Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncology, The, 2019, 20, 746-748.	10.7	5
61	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Current Oncology Reports, 2019, 21, 25.	4.0	122
62	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nature Cell Biology, 2019, 21, 190-202.	10.3	384
63	Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?. Expert Opinion on Investigational Drugs, 2019, 28, 107-112.	4.1	8
64	Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1004-1004.	1.6	19
65	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, 1028-1028.	1.6	5
66	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1057-1057.	1.6	27
67	HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.. Journal of Clinical Oncology, 2019, 37, 502-502.	1.6	65
68	Implementation of a brief screening tool to identify needs of cancer survivors.. Journal of Clinical Oncology, 2019, 37, e23075-e23075.	1.6	1
69	Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clinical Cancer Research, 2018, 24, 2981-2983.	7.0	5
70	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Research and Treatment, 2018, 172, 733-740.	2.5	15
71	Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Reports, 2018, 4, 452-454.	0.8	17
72	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discovery, 2018, 8, 1286-1299.	9.4	85

#	ARTICLE	IF	CITATIONS
73	SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?. <i>Lancet Oncology</i> , The, 2017, 18, 564-565.	10.7	1
74	Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1169-1176.	3.1	9
75	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. <i>Oncologist</i> , 2017, 22, 1039-1048.	3.7	115
76	Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1767-1772.	2.0	23
77	Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 113-118.	2.0	6
78	Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. <i>Cancer</i> , 2017, 123, 401-409.	4.1	10
79	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	3.0	6
80	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046.	1.6	4
81	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1106-TPS1106.	1.6	1
82	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1477.	7.1	259
83	Abstract 1439: Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. <i>Cancer Research</i> , 2016, 76, 1439-1439.	0.9	8
84	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 586-586.	1.6	0
85	Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. <i>Discovery Medicine</i> , 2016, 21, 65-74.	0.5	59
86	Risk Factors for Readmission after Allogeneic Hematopoietic Stem Cell Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 509-516.	2.0	32